Status:
COMPLETED
mTOR Inhibitors: the Lesions Induced by Papillomavirus for Transplant Patients.
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Transplantation Organ
Eligibility:
All Genders
18+ years
Brief Summary
The injuries induced by Human Papillomavirus (HPV) (anogenital condyloma mainly) are more frequent among transplanted patients due to their immunosuppression. These injuries are benign but they have a...
Eligibility Criteria
Inclusion
- Adult patient (Age ≥ 18 years)
- Transplanted patient (any organ), having developed HPV-induced lesions after transplantation
- Patient followed or having been followed at Edouard Herriot Hospital (HEH)
- Patient having been informed and not having objected to participating in the study
Exclusion
- Transplanted patient without HPV-induced lesions
Key Trial Info
Start Date :
February 14 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 31 2022
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT05198427
Start Date
February 14 2022
End Date
March 31 2022
Last Update
April 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Edouard Herriot
Lyon, Auvergne-Rhône-Alpes, France, 69003